Literature DB >> 8628270

Three functional classes of transcriptional activation domain.

J Blau1, H Xiao, S McCracken, P O'Hare, J Greenblatt, D Bentley.   

Abstract

We have studied the abilities of different transactivation domains to stimulate the initiation and elongation (postinitiation) steps of RNA polymerase II transcription in vivo. Nuclear run-on and RNase protection analyses revealed three classes of activation domains: Sp1 and CTF stimulated initiation (type I); human immunodeficiency virus type 1 Tat fused to a DNA binding domain stimulated predominantly elongation (type IIA); and VP16, p53, and E2F1 stimulated both initiation and elongation (type IIB). A quadruple point mutation of VP16 converted it from a type IIB to a type I activator. Type I and type IIA activators synergized with one another but not with type IIB activators. This observation implies that synergy can result from the concerted action of factors stimulating two different steps in transcription: initiation and elongation. The functional differences between activators may be explained by the different contacts they make with general transcription factors. In support of this idea, we found a correlation between the abilities of activators, including Tat, to stimulate elongation and their abilities to bind TFIIH.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8628270      PMCID: PMC231191          DOI: 10.1128/MCB.16.5.2044

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  76 in total

1.  Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor.

Authors:  C H Herrmann; A P Rice
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

2.  The MO15 cell cycle kinase is associated with the TFIIH transcription-DNA repair factor.

Authors:  R Roy; J P Adamczewski; T Seroz; W Vermeulen; J P Tassan; L Schaeffer; E A Nigg; J H Hoeijmakers; J M Egly
Journal:  Cell       Date:  1994-12-16       Impact factor: 41.582

Review 3.  Control of RNA initiation and elongation at the HIV-1 promoter.

Authors:  K A Jones; B M Peterlin
Journal:  Annu Rev Biochem       Date:  1994       Impact factor: 23.643

Review 4.  The multifunctional TFIIH complex and transcriptional control.

Authors:  R Drapkin; D Reinberg
Journal:  Trends Biochem Sci       Date:  1994-11       Impact factor: 13.807

5.  Cloning of an intrinsic human TFIID subunit that interacts with multiple transcriptional activators.

Authors:  C M Chiang; R G Roeder
Journal:  Science       Date:  1995-01-27       Impact factor: 47.728

6.  Association of Cdk-activating kinase subunits with transcription factor TFIIH.

Authors:  H Serizawa; T P Mäkelä; J W Conaway; R C Conaway; R A Weinberg; R A Young
Journal:  Nature       Date:  1995-03-16       Impact factor: 49.962

7.  Relationship of CDK-activating kinase and RNA polymerase II CTD kinase TFIIH/TFIIK.

Authors:  W J Feaver; J Q Svejstrup; N L Henry; R D Kornberg
Journal:  Cell       Date:  1994-12-16       Impact factor: 41.582

8.  Transcriptional activators differ in their responses to overexpression of TATA-box-binding protein.

Authors:  Y Sadovsky; P Webb; G Lopez; J D Baxter; P M Fitzpatrick; E Gizang-Ginsberg; V Cavailles; M G Parker; P J Kushner
Journal:  Mol Cell Biol       Date:  1995-03       Impact factor: 4.272

9.  Novel mechanism and factor for regulation by HIV-1 Tat.

Authors:  Q Zhou; P A Sharp
Journal:  EMBO J       Date:  1995-01-16       Impact factor: 11.598

10.  Serum-regulated transcription by serum response factor (SRF): a novel role for the DNA binding domain.

Authors:  C S Hill; J Wynne; R Treisman
Journal:  EMBO J       Date:  1994-11-15       Impact factor: 11.598

View more
  116 in total

1.  hnRNP U inhibits carboxy-terminal domain phosphorylation by TFIIH and represses RNA polymerase II elongation.

Authors:  M K Kim; V M Nikodem
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

2.  A general strategy to enhance the potency of chimeric transcriptional activators.

Authors:  S Natesan; E Molinari; V M Rivera; R J Rickles; M Gilman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

Review 3.  P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II.

Authors:  D H Price
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

4.  The role of AHA motifs in the activator function of tomato heat stress transcription factors HsfA1 and HsfA2.

Authors:  P Döring; E Treuter; C Kistner; R Lyck; A Chen; L Nover
Journal:  Plant Cell       Date:  2000-02       Impact factor: 11.277

5.  Transcriptional activation by artificial recruitment in mammalian cells.

Authors:  J Nevado; L Gaudreau; M Adam; M Ptashne
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

6.  Discrete promoter elements affect specific properties of RNA polymerase II transcription complexes.

Authors:  J W Steinke; S J Kopytek; D O Peterson
Journal:  Nucleic Acids Res       Date:  2000-07-15       Impact factor: 16.971

7.  The transcription elongation factor CA150 interacts with RNA polymerase II and the pre-mRNA splicing factor SF1.

Authors:  A C Goldstrohm; T R Albrecht; C Suñé; M T Bedford; M A Garcia-Blanco
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

8.  Transcriptional analyses of antifungal drug resistance in Candida albicans.

Authors:  C N Lyons; T C White
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

9.  The VP16 paradox: herpes simplex virus VP16 contains a long-range activation domain but within the natural multiprotein complex activates only from promoter-proximal positions.

Authors:  M Hagmann; O Georgiev; W Schaffner
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

10.  HIFs enhance the transcriptional activation and splicing of adrenomedullin.

Authors:  Johnny A Sena; Liyi Wang; Matthew R Pawlus; Cheng-Jun Hu
Journal:  Mol Cancer Res       Date:  2014-02-12       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.